Full-text resources of PSJD and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl


Preferences help
enabled [disable] Abstract
Number of results


2014 | 9 | 6 | 748-753

Article title

Markers of inflammation and microvascular complications in type 1 diabetes


Title variants

Languages of publication













Physical description


1 - 12 - 2014
16 - 8 - 2014


  • Clinic for Endocrinology, Diabetes and Metabolic Disorders, Clinical Center of Vojvodina, Medical Faculty, University of Novi Sad, Novi Sad, Serbia
  • Clinic for Endocrinology, Diabetes and Metabolic Disorders, Clinical Center of Vojvodina, Medical Faculty, University of Novi Sad, Novi Sad, Serbia
  • Clinic for Endocrinology, Diabetes and Metabolic Disorders, Clinical Center of Vojvodina, Medical Faculty, University of Novi Sad, Novi Sad, Serbia
  • Clinic for Endocrinology, Diabetes and Metabolic Disorders, Clinical Center of Vojvodina, Medical Faculty, University of Novi Sad, Novi Sad, Serbia
  • Clinic for Nephrology and Clinical Immunology, Clinical Center of Vojvodina, Medical Faculty, University of Novi Sad, Novi Sad, Serbia
  • Clinic for Endocrinology, Diabetes and Metabolic Disorders, Clinical Center of Vojvodina, Medical Faculty, University of Novi Sad, Novi Sad, Serbia


  • [1] Maiti R, Agrawal NK. Atherosclerosis in diabetes mellitus: role of inflammation. Indian J Med Sci 2007;61:292–306 http://dx.doi.org/10.4103/0019-5359.32098[Crossref]
  • [2] Kilpatrick ES, Keevil BG, Jagger C, Spooner RJ, Smalla M. Determinants of raised C reactive protein concentration in type 1 diabetes. Q J Med 2000;93:231–233 http://dx.doi.org/10.1093/qjmed/93.4.231[Crossref]
  • [3] Chase HP, Cooper S, Osberg I, Stene L, Barriga K, Norris J, et al. Elevated C reactive protein levels in the development of type 1 diabetes. Diabetes 2004;53:2569–2573 http://dx.doi.org/10.2337/diabetes.53.10.2569[Crossref]
  • [4] Devaraj S, Glaser N, Griffen S, Wang-Polgruto J, Miguelino E, Jialal I. Increased monocytic activity and biomarkers of inflammation in patients with type 1 diabetes. Diabetes 2006;55:774–779 http://dx.doi.org/10.2337/diabetes.55.03.06.db05-1417[Crossref]
  • [5] Targher G, Zenari L, Bertoloini L, Muggeo G. Elevated levels of interleukin-6 in young adults with type 1 diabetes without clinical evidence of microvascular complications. Diabetes Care 2001;24:956–957 http://dx.doi.org/10.2337/diacare.24.5.956[Crossref]
  • [6] Sibal L, Aldibbiat A, Agarwal SC, Mitchell G, Oates C, Razvi S, et al. Circulating endothelial progenitor cells, endothelial function, carotid intima-media thickness and circulating markers of endothelial dysfunction in people with type 1 diabetes without macrovascular disease or microalbuminuria. Diabetologia 2009;52:1464–1473 http://dx.doi.org/10.1007/s00125-009-1401-0[WoS][Crossref]
  • [7] Pepys MB, Hirshfield GM. C reactive protein: a critical update. J Clin Invest 2003;111 (12):1805–12 http://dx.doi.org/10.1172/JCI200318921[Crossref]
  • [8] Kishimoto T. IL-6: from its discovery to clinical applications. Int Immunol 2010;22 (5):347–352 http://dx.doi.org/10.1093/intimm/dxq030[Crossref]
  • [9] Jurisic V, Srdic-Rajic T, Konjevic G, Bogdanovic G, Colic M. TNF-α induced apoptosis is accompanied with rapid CD30 and slower CD45 shedding from K-562 cells. J Membr Biol 2011;239 (3):115–122 http://dx.doi.org/10.1007/s00232-010-9309-7[WoS][Crossref]
  • [10] Fraser GE, Luke R, Thompson S, Smith H, Carter S, Sharpe N. Comparison of echocardiographic variables between type I diabetics and normal control. Am J Cardiol 1995;75:141–145 http://dx.doi.org/10.1016/S0002-9149(00)80063-6[Crossref]
  • [11] Venugopal SK, Devaraj S, Jialal I. Effect of C reactive protein on vascular cells: evidence for a proinflammatory, proatherogenic role. Curr Opin Nephrol Hypertens 2005;14:33–37 http://dx.doi.org/10.1097/00041552-200501000-00006[Crossref]
  • [12] Zorena K, Mysliwska J, Mysliwiec M, Balcerska A, Lipowski P, Raczynska K. Relationship between serum levels of tumor necrosis factor-alpha and interleukin-6 in diabetes mellitus type 1 children. Centr Eur Immunol 2007;32 (3):124–128
  • [13] Schalkwijk CG, Poland DC, van Dijk W, Kok A, Emeis JJ, Drager AM, et al. Plasma concentration of C reactive protein is increased in type I diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: Evidence for chronic inflammation. Diabetologia 1999;42:351–357 http://dx.doi.org/10.1007/s001250051162[Crossref]
  • [14] Schram MT, Chaturvedi N, Schalkwijk CG, Fuller JH, Stehouwer CDA. Markers of inflammation are cross-sectionally associated with microvascular complications and cardiovascular disease in type 1 diabetes-the EURODIAB Prospective Complications Study. Diabetologia 2005;48:370–378 http://dx.doi.org/10.1007/s00125-004-1628-8[Crossref]
  • [15] Chaturvedi N, Fuller JH, Taskinen MR. EURODIAB study group: Differing associations of lipid and lipoprotein disturbances with macrovascular and microvascular complications of type 1 diabetes. Diabetes Care 2001;24:2071–2077 http://dx.doi.org/10.2337/diacare.24.12.2071[Crossref]
  • [16] Chambers JC, Eda S, Bassett P, Karim Y, Thompson SG, Gallimore JR et al. C reactive protein, insulin resistance, central obesity and coronary heart disease risk in Indian Asians from United Kingdom compared with Europian whites. Circulation 2001;104:145–150 http://dx.doi.org/10.1161/01.CIR.104.2.145[Crossref]
  • [17] Jurisic V, Terzic T, Colic S, M Jurisic. The concentration of TNF-α correlate with number of inflammatory cells and degree of vascularization in radicular cysts. Oral Dis 2008;14(7):600–605 http://dx.doi.org/10.1111/j.1601-0825.2007.01426.x[Crossref][WoS]
  • [18] Lopes Virella MF, Carter RE, Gilbert GE, Klein RL, Jaffa M, Jenkins A. Risk factors related to inflammation and endothelial dysfunction in the DCCT/EDIC cohort and their relationship with nephropathy and macrovascular complications. Diabetes Care 2008;31:2006–2012 http://dx.doi.org/10.2337/dc08-0659[WoS][Crossref]
  • [19] Ladeia AM, Stefanelli E, Ladeia-Frota C, Moreira A, Hiltner A, Adan L. Association between elevated serum C reactive protein and triglyceride levels in young subjects with type 1 diabetes. Diabetes Care 2005;29 (2):424–426
  • [20] Frank RN. Diabetic retinopathy. N Engl J Med 2004;350:48–58 http://dx.doi.org/10.1056/NEJMra021678[Crossref]
  • [21] Elner SG, Elner VM, Jaffe GJ, Stuart A, Kunkel SL, Strieter RM. Cytokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy. Curr Eye Res 1995;14:1045–1053 http://dx.doi.org/10.3109/02713689508998529[Crossref]
  • [22] Limb GA, Hollifield RD, Webster L, Charteris DG, Chignell AH. Soluble TNF receptors in vitreoretinal proliferative disease. Invest Ophtalmol Vis Sci 2001;42:1586–1591
  • [23] Skundric DS, Robert P. Role of neuropoetic cytokines in development and progression of diabetic polyneuropathy: From glucose metabolism to neurodegeneration. Experimental Diab Res 2003;4:303–312 http://dx.doi.org/10.1155/EDR.2003.303[Crossref]
  • [24] Herder C, Lankish M, Ziegler D, Rathmann W, Koenig W, Illig T, et al. Subclinical inflammation and diabetic polyneuropathy. Diabetes Care 2009;32 (4):680–682 http://dx.doi.org/10.2337/dc08-2011[WoS][Crossref]
  • [25] Haaber AB, Deckert M, Stender S, Jensen T. Increases urinary loss of high density lipoproteins in albuminuric insulin dependent diabetic patients. Scand J Clin Lab Invest 1993;53:191–196 http://dx.doi.org/10.3109/00365519309088407[Crossref]
  • [26] Vaziri ND, Liang K. Up-regulation of acyl-coenzyme A: cholesterol acyltransferase (ACTA) in nephritic syndrome. Kidney Int 2002;62 (5):1769–1775 http://dx.doi.org/10.1046/j.1523-1755.2002.00319.x[Crossref]
  • [27] Gedela S, Guruju VPB, Sulakshana M, Meheswari IL, Prabhakar T, Sankar G, et al. Quantitative analysis of cytokines in diabetic nephropathy. Journal Proteomics Bioinform 2009;2:217–221 http://dx.doi.org/10.4172/jpb.1000079[Crossref]
  • [28] Joles JA, Kunter U, Janssen U, Kriz W, Rabelink TJ, Koomans HA, et al. Early mechanisms of renal injury in hyperholesterolemic or hypertriglyceridemic rats. J Am Soc Nephrol 2000;11:669–683 [PubMed]
  • [29] Rivellese AA, Vaccuaro O, Patti L. The patophysiology of lipid metabolism and diabetes. Int J of Clin Pract 2004;58:32–35 http://dx.doi.org/10.1111/j.1368-504X.2004.00332.x[Crossref]
  • [30] Schram M, Chaturvedi N, Schalkwijk C, Giorgino F, Ebeling P, Fuller JH, et al. The EURODIAB Prospective Complications Study Group: Vascular risk factors and markers of endothelial function as determinants of inflammatory markers in type 1 diabetes. Diabetes Care 2003;26 (7):2165–2173 http://dx.doi.org/10.2337/diacare.26.7.2165
  • [31] Guy J, Ogden L, Wadwa RP, Hamman RF, Mayer-Davis EJ, Liese AD, et al. Lipid and lipoprotein pro-files in youth with and without type 1 diabetes. The search for diabetes in youth case-control study. Diabetes Care 2009;32(3):416–420 http://dx.doi.org/10.2337/dc08-1775

Document Type

Publication order reference


YADDA identifier

JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.